Baligadoo S J, Subratty H, Manraz M, Tarral A, Maiti D, Murday M
SSR Centre for Medical Studies and Research, School of Science, University of Mauritius, France.
Int J Cardiol. 1990 Jul;28 Suppl 1:S29-32. doi: 10.1016/0167-5273(90)90148-x.
To assess whether an inotropic agent may affect quality of life in severe heart failure, a double-blind, placebo-controlled crossover study was performed in 10 patients over three periods of 3 weeks, including an initial control period of 3 weeks and periods on placebo or enoximone, 150 mg t.d.s. Quality of life was assessed by a questionnaire following initial training of patients to evaluate their symptoms after certain stresses, by visual analogue scales of symptoms, and by objective assessments during graded exercise. Daily dyspnoea score decreased from 33.2 +/- 2 (placebo) to 27.7 +/- 4 (enoximone) (P less than 0.01) and daily fatigue score decreased from 14.8 +/- 2.5 (placebo) to 12.6 +/- 2 (enoximone) (P less than 0.05). There were also significant beneficial responses in the mean daily NYHA class and in the duration of a walking test. Self-assessed global quality of life score increased from 2.7 +/- 0.6 (placebo) to 3.6 +/- 0.8 (enoximone) (P less than 0.05). It was concluded that over periods of 3 weeks, enoximone significantly improved self-assessed quality of life.
为评估一种强心剂是否会影响重度心力衰竭患者的生活质量，对10例患者进行了一项双盲、安慰剂对照的交叉研究，为期3个3周周期，包括一个为期3周的初始对照期以及服用安慰剂或依诺昔酮（150毫克，每日三次）的周期。通过在对患者进行初始培训后使用问卷来评估他们在特定应激后的症状，通过症状视觉模拟量表，以及通过分级运动期间的客观评估来评估生活质量。每日呼吸困难评分从（安慰剂组）33.2±2降至（依诺昔酮组）27.7±4（P<0.01），每日疲劳评分从（安慰剂组）14.8±2.5降至（依诺昔酮组）12.6±2（P<0.05）。在平均每日纽约心脏协会（NYHA）心功能分级和步行试验持续时间方面也有显著的有益反应。自我评估的总体生活质量评分从（安慰剂组）2.7±0.6提高到（依诺昔酮组）3.6±0.8（P<0.05）。得出的结论是，在3周的时间里，依诺昔酮显著改善了自我评估的生活质量。
